ClinicalTrials.gg
RecruitingNCT07684144Updated Oct 5, 2026

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

A Phase 3 interventional study of Maridebart Cafraglutide and Placebo in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Amgen. Recruiting at 45 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 5, 2026First sites in Canada and United Kingdom12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
950
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Planned enrollment
7th of 28
950 · median 275
Started
2026
with 9 others
Phase 3
11 of 28
6 open now
Primary completion
2027-12
later than 10 of 16 live
Registered
21st of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 7th largest by planned enrollment, is one of 10 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 10 of the 16 other live ones, and was the 21st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

03

Conditions studied

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 Diabetes Mellitus
  • T2DM
  • BMI
  • Obesity
  • Overweight
  • Maridebart Cafraglutide
  • MariTide
  • Chronic Weight Management
  • Extension
  • Long-Term
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form (ICF) indicating compliance with the requirements and restrictions listed in the ICF and this protocol.
  • Participants completing Study 20210184 must meet the following criteria:

    • Completed the Week 72 visit in Study 20210184.
    • Did not permanently discontinue the product in the parent trial (20210184).
    • Randomized within 7 days of week 72 visit in the parent trial.
  • Participants must use protocol-specified during treatment and for 16 weeks after the last dose of trial intervention.

Exclusion criteria

Exclusion Criteria:

  • Planned (during the trial) surgical, endoscopic, or device-based treatment for obesity.
  • (BMI) ≤ 18.5 kilograms per meter square (kg/m\^2).
  • Participant has known sensitivity to any of the products or components to be administered during dosing.
  • History of ischemic optic neuropathy.
  • Any diagnosed during the parent trial, except for the following treated with curative intent:

    • Nonmelanoma skin cancers
    • Breast ductal carcinoma in situ
    • Cervical carcinoma in situ
    • Prostate cancer in situ
  • Newly identified (during the parent trial) multiple endocrine neoplasia syndrome type 2, or family history (first-degree relative[s]) history of medullary thyroid carcinoma (MTC).
  • Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at the Week 72 visit from the parent trial (20210184) before randomization.
  • Any suicidal ideation (category 4 or 5) or any suicidal behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS), Since Last Visit version, at the Week 72 visit from the parent trial before randomization.
  • Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator.
  • History or evidence of any other disorder, condition, disease (including, but not limited to known drug or alcohol abuse, eating disorders, and conditions identified during the parent trial) that, in the opinion of the investigator, would pose a risk to participant safety.
  • Currently pregnant (confirmed with positive pregnancy test) or breastfeeding or planning to become pregnant or breastfeed while on trial until an additional 16 weeks after the last dose of trial intervention.
  • Major surgical procedures planned during the trial.
  • Participants with minor surgical procedures (not requiring general anesthesia or deep sedation) planned during the trial may be eligible at the discretion of the investigator.
  • Investigative site personnel directly affiliated with the trial and/or their immediate family (ie, spouse, parent, child, or sibling, whether biological or legally adopted).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
950 participants (estimated)

Study arms

  • Experimental
    Maridebart Cafraglutide Low Dose Q4W

    Participants who received low dose of maridebart cafraglutide in the parent trial (20210184 \[NCT06858878\]) will continue to receive low dose of maridebart cafraglutide subcutaneously (SC) once in 4 weeks (Q4W).

    Drug: Maridebart Cafraglutide

  • Experimental
    Maridebart Cafraglutide Medium Dose Q4W

    Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive medium dose of maridebart cafraglutide SC Q4W.

    Drug: Maridebart Cafraglutide

  • Experimental
    Maridebart Cafraglutide Medium dose Q8W

    Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive medium dose of maridebart cafraglutide SC once in 8 weeks (Q8W).

    Drug: Maridebart Cafraglutide

  • Placebo comparator
    Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)

    Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive placebo SC Q4W.

    Drug: Placebo

  • Experimental
    Maridebart Cafraglutide High Dose Q4W

    Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive high dose of maridebart cafraglutide SC Q4W.

    Drug: Maridebart Cafraglutide

  • Experimental
    Maridebart Cafraglutide High Dose Q8W

    Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive high dose of maridebart cafraglutide SC Q8W.

    Drug: Maridebart Cafraglutide

  • Placebo comparator
    Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)

    Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive placebo SC Q4W.

    Drug: Placebo

  • Experimental
    Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)

    Participants who received placebo in the parent trial will receive high dose of maridebart cafraglutide SC Q4W. Prior to initiating the assigned high dose, participants will undergo a dose-escalation phase gradually increasing doses.

    Drug: Maridebart Cafraglutide

  • Experimental
    Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)

    Participants who permanently de-escalated to very low dose of maridebart cafraglutide in the parent trial will receive low dose of maridebart cafraglutide SC Q4W.

    Drug: Maridebart Cafraglutide

Interventions

  • Administered subcutaneously.

    Also known as: AMG 133, MariTide

  • DrugPlacebo

    Administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight from Baseline of the Parent Trial (20210184)

    Time frame: Baseline of parent trial (20210184) to Week 48 of current trial

  2. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline of current trial up to 60 weeks

Secondary outcomes

  1. Percentage of Participants Achieving ≥ 5% Reduction in Body Weight from Baseline of the Parent Trial

    Time frame: Baseline of parent trial to Week 48 of current trial

  2. Percentage of Participants Achieving ≥ 10% Reduction in Body Weight from Baseline of the Parent Trial

    Time frame: Baseline of parent trial to Week 48 of current trial

  3. Percentage of Participants Achieving ≥ 15% Reduction in Body Weight from Baseline of the Parent Trial

    Time frame: Baseline of parent trial to Week 48 of current trial

  4. Percentage of Participants Achieving ≥ 20% Reduction in Body Weight from Baseline of the Parent Trial

    Time frame: Baseline of parent trial to Week 48 of current trial

  5. Change from Baseline of the Parent Trial in Hemoglobin A1c

    Time frame: Baseline of parent trial to Week 48 of current trial

  6. Change from Baseline of the Parent Trial in Waist Circumference

    Time frame: Baseline of parent trial to Week 48 of current trial

  7. Change from Baseline of the Parent Trial in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    Time frame: Baseline of parent trial to Week 48 of current trial

  8. Percent Change from Baseline in Body Weight

    Time frame: Baseline of current trial to Week 48

  9. Percentage of Participants with No Body Weight Gain of >3% From Baseline

    Time frame: Week 48 of current trial

  10. Percentage of Participants with No Body Weight Gain of >5% From Baseline

    Time frame: Week 48 of current trial

  11. Percentage of Body Weight Reduction Maintained from the Parent Trial

    Time frame: Baseline of parent trial to Week 48 of current trial

  12. Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved in the Parent Trial

    Time frame: Baseline of parent trial to Week 48 of current trial

  13. Change from Baseline in HbA1c

    Time frame: Week 48 of current trial

07

Study locations

45 of 45 sites recruiting
  • Gilbert Center for Family Medicine
    Gilbert, Arizona 85296, United States
    Recruiting
  • San Fernando Valley Health Institute
    Canoga Park, California 91304, United States
    Recruiting
  • Core Healthcare Group
    Cerritos, California 90703, United States
    Recruiting
  • Velocity Clinical Research Chula Vista
    La Mesa, California 91942, United States
    Recruiting
  • Paradigm Clinical Research
    Modesto, California 95355, United States
    Recruiting
  • Empire Clinical Research
    Pomona, California 91767, United States
    Recruiting
  • San Marcus Research Clinic Inc
    Miami, Florida 33015, United States
    Recruiting
  • Optimus U Corporation
    Miami, Florida 33135, United States
    Recruiting
  • Indago Research and Health Center
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Florida Institute for Clinical Research
    Orlando, Florida 32825, United States
    Recruiting
  • Encore Medical Research of Weston LLC
    Weston, Florida 33331, United States
    Recruiting
  • Conquest Research - Winter Park
    Winter Park, Florida 32789, United States
    Recruiting
  • Endeavor Health
    Skokie, Illinois 60077, United States
    Recruiting
  • Iowa Diabetes Research
    West Des Moines, Iowa 50266, United States
    Recruiting
  • JCCT- Juno Northwest Houston
    Lenexa, Kansas 66219, United States
    Recruiting
  • Alliance for Multispecialty Research Newton
    Newton, Kansas 67114, United States
    Recruiting
  • Alliance for Multispecialty Research LLC
    Wichita, Kansas 67226, United States
    Recruiting
  • Ima Clinical Research- Monroe
    Monroe, Louisiana 71201, United States
    Recruiting
  • Annapolis Internal Medicine, LLC
    Annapolis, Maryland 21401, United States
    Recruiting
  • Alliance for Multispecialty Research - Kansas City
    Kansas City, Missouri 64114, United States
    Recruiting
  • Palm Research Center Inc
    Las Vegas, Nevada 89148, United States
    Recruiting
  • Premier Research
    Trenton, New Jersey 08611, United States
    Recruiting
  • West Clinical Research
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Velocity Clinical Research - Cincinnati
    Cincinnati, Ohio 45242, United States
    Recruiting
  • Velocity Clinical Research - Springdale
    Cincinnati, Ohio 45246, United States
    Recruiting
  • Velocity Clinical Research - Providence
    East Greenwich, Rhode Island 02818, United States
    Recruiting
  • Elligo Clinical Research Center
    Austin, Texas 78704, United States
    Recruiting
  • Johnson County Clinical Trials Juno Bellaire
    Bellaire, Texas 77401, United States
    Recruiting
  • Osvaldo A Brusco MD PA
    Corpus Christi, Texas 78414, United States
    Recruiting
  • Soma Clinical Trials, LLC
    Denison, Texas 75020, United States
    Recruiting
  • Manassas Clinical Research Center Inc
    Burke, Virginia 22015, United States
    Recruiting
  • Hamilton Medical Research Group
    Hamilton, Ontario L8L 5G4, Canada
    Recruiting
  • Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
    Matsuyama, Ehime 790-0034, Japan
    Recruiting
  • Morizono Medical Clinic
    Kitakyusyu-shi, Fukuoka 807-0072, Japan
    Recruiting
  • Mazda Hospital of Mazda Motor Corporation
    Aki-gun, Hiroshima 735-8585, Japan
    Recruiting
  • Nakamoto Medical Clinic
    Mito, Ibaraki 310-0826, Japan
    Recruiting
  • Nakakinen Clinic
    Naka, Ibaraki 311-0113, Japan
    Recruiting
  • Ohishi Naika Clinic
    Tsuchiura-shi, Ibaraki 300-0835, Japan
    Recruiting
  • Morinaga Ueno Clinic
    Kumamoto, Kumamoto 860-0863, Japan
    Recruiting
  • Shiraiwa Medical Clinic
    Kashiwara-shi, Osaka 582-0005, Japan
    Recruiting
  • Suruga Clinic
    Shizuoka, Shizuoka 424-0855, Japan
    Recruiting
  • Yutenji Medical Clinic
    Meguro-ku, Tokyo 153-0053, Japan
    Recruiting
  • Medical Corporation Ouitsukai Kanno Naika
    Mitaka-shi, Tokyo 181-0013, Japan
    Recruiting
  • Latin Clinical Trial Center
    San Juan, 00909, Puerto Rico
    Recruiting
  • FutureMeds Birmingham
    Birmingham, B21 9RY, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 16 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Dec 26, 2027
CompletionEst.
Mar 19, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 4 sites removed — first sites in Canada and United Kingdom
Show 12 added (8 United States, 2 Japan, 1 Canada, 1 United Kingdom)
  • Velocity Clinical Research Chula Vista · La Mesa, United States
  • Paradigm Clinical Research · Modesto, United States
  • San Marcus Research Clinic Inc · Miami, United States
  • Endeavor Health · Skokie, United States
  • JCCT- Juno Northwest Houston · Lenexa, United States
  • Ima Clinical Research- Monroe · Monroe, United States
  • Annapolis Internal Medicine, LLC · Annapolis, United States
  • Manassas Clinical Research Center Inc · Burke, United States
  • Hamilton Medical Research Group · Hamilton, Canada
  • Mazda Hospital of Mazda Motor Corporation · Aki-gun, Japan
  • Yutenji Medical Clinic · Meguro-ku, Japan
  • FutureMeds Birmingham · Birmingham, United Kingdom
Show 4 removed
  • Velocity Clinical Research Chula Vista · Chula Vista, United States
  • San Marcus Research Clinic Inc · Miami Lakes, United States
  • JCCT- Juno Northwest Houston · Houston, United States
  • Manassas Clinical Research Center Inc · Manassas, United States
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    12 sites added, 4 sites removed — first sites in Canada and United Kingdom
    Show 12 added (8 United States, 2 Japan, 1 Canada, 1 United Kingdom)
    • Velocity Clinical Research Chula Vista · La Mesa, United States
    • Paradigm Clinical Research · Modesto, United States
    • San Marcus Research Clinic Inc · Miami, United States
    • Endeavor Health · Skokie, United States
    • JCCT- Juno Northwest Houston · Lenexa, United States
    • Ima Clinical Research- Monroe · Monroe, United States
    • Annapolis Internal Medicine, LLC · Annapolis, United States
    • Manassas Clinical Research Center Inc · Burke, United States
    • Hamilton Medical Research Group · Hamilton, Canada
    • Mazda Hospital of Mazda Motor Corporation · Aki-gun, Japan
    • Yutenji Medical Clinic · Meguro-ku, Japan
    • FutureMeds Birmingham · Birmingham, United Kingdom
    Show 4 removed
    • Velocity Clinical Research Chula Vista · Chula Vista, United States
    • San Marcus Research Clinic Inc · Miami Lakes, United States
    • JCCT- Juno Northwest Houston · Houston, United States
    • Manassas Clinical Research Center Inc · Manassas, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07684144
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jul 29, 2026
Primary completion
Dec 26, 2027 (estimated)
Completion
Mar 19, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion